1. When Is Adding Aspirin to NOACs Worth the Risk?

2. Patient Presentation

3. Patient Presentation (cont)

4. Assessing Risk CHA2DS2-VASc

5. Stroke Prevention in AF

6. Managing AF and CAD

7. Concomitant Use of Antiplatelets and Edoxaban in Patients With AF: Study Design

8. Concomitant Antiplatelet and NOAC Therapy: Outcomes in Patients With AF

9. Efficacy of NOACs vs Warfarin in SPAF Trials: Stroke or SEE

10. Efficacy of Edoxaban vs Warfarin in Patients With AF on Antiplatelet Therapy

11. Safety of Edoxaban vs Warfarin in Patients With AF on Antiplatelet Therapy

12. Assessing a Patient With CAD and AF

13. ICH in Asian vs Non-Asian Patients With AF

14. Safety of Edoxaban vs Warfarin in East Asian Patients With AF

15. Which NOAC? Factors to Consider

16. Recommendations for Stroke Prevention in Patients With AF

17. Antithrombotic Therapy After an ACS

18. Abbreviations

19. Abbreviations (cont)

20. Abbreviations (cont)